Why We’re Optimistic About Alzheimer’s Research

Why We’re Optimistic About Alzheimer’s Research
This year also marks the 10th Clinical Trials on Alzheimer’s Disease (CTAD) conference, currently taking place in Boston. The meeting brings together worldwide leaders to discuss new results and issues important to the development of the next generation of treatments for this devastating disease. Spending nearly 30 years in the lab conducting clinical studies, Lilly scientists are among those leaders.

And similar to the iPhone, the work we do today in Alzheimer’s was not even conceivable when the first CTAD meeting took place in 2007. While it is disappointing to analyze trials that have not been successful, each time we do, we learn a great deal and are able to apply those critical insights to subsequent studies, further advancing the science. Here at Lilly, we are committed to continue leading in the diagnosis and treatment of Alzheimer’s disease and are optimistic we will have meaningful ability to either prevent or significantly delay the onset of the disease within the next 10 years.

New Knowledge Yields New Approaches to Research
With each clinical trial, we gain an invaluable amount of knowledge about the disease. Scientists are significantly expanding how and what they are researching. Within the last few years, we’ve learned earlier is better and we are pleased to have six different treatments in our pipeline which focus on early intervention. We are starting to look at Alzheimer’s disease more like cancer -- fatal and progressive -- and treat it as early and aggressively as we can. Our ability to detect Alzheimer’s pathology earlier and earlier provides us with a great window for prevention and I believe that’s where we’re going to see the most progress over the next 10 years.


Categories: News
Rate this article:
No rating